Member Info for L2analyst

Bid price significantly strengthening up expects 10p soon

Fomo will kick in specially when they are saying moving towards collaborations and new asset to be added in soon

Company moving towards collaborations that is big news second from takeover

Almost back in blue

L2 strengthen nicely!

Sp angel would want a significant return

"The Placing, which was significantly oversubscribed, was undertaken by SP Angel Corporate Finance LLP.

Added another small amount 12k at 8.70p

You don't move into collaborations unless you have something that works and the big pharmaceutical companies need it!

A partnership name will see this sky high share price

"as we move towards collaborations."

Looks like they can use nuvec on multiple existing and new vaccines.

"we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.

"With vaccines and their delivery very much in the public consciousness we continue to grow our data package to present Nuvec® as a viable delivery technology solution to improve the delivery, storage and transportation of multiple existing and new vaccines.

 

Placing price took the headline but the rns is actually more positive then the placing, read it again guys

Looks to me they are already in talks with potential partners

"we move towards collaborations.

Getting quotes to buy at 8.719p and these will show sell because price is just below midpoint but its actually buys, 10p close

Look at ncyt, sng etc they done similar placing and look where the share price is

8.74p to buy so they are premium now,

Yep buys comming through fast, sp angel hinting at partnership and they undertaken all the placing something brewing for sure

Outlook: N4 Pharma is well-positioned to offer developers an alternate delivery approach for their DNA/RNA-based vaccine candidates. Supported by cash from a placing in May, N4P is nearing completion of its COVID-19 programme. Positive results from this project would be a significant milestone for the Group. Through the optimisation programme N4 Pharma looks to progress Nuvec® to a stage where it can seek licencing agreements. We expect interest from potential partners seeking to use Nuvec® as part of their development programme for nucleic acid-based products.

https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf

Majority of aims ceo are scums worse then Nigerians fraudster but thats how it is here anyway another rns due shorty

"research on and evaluation of an additional asset to add to the Company portfolio;

Totally agree , you don't get money for nothing hold tight guys

Well there's next news imminent according to this rns, best to average up